Research News
View articles by month and year
1–3 of 3 articles
-
Vitamin D Levels May Be Reason Some Women Benefit from Zometa Added to Chemo
New results from a large study suggest that postmenopausal women diagnosed with early-stage breast cancer who had adequate vitamin D levels got more benefits from Zometa combined with chemotherapy than women who had low vitamin D levels.
-
Oral Bisphosphonates Don’t Seem to Reduce Recurrence Risk
Two studies found that two oral bisphosphonates didn't reduce recurrence risk for women diagnosed with early-stage breast cancer.
-
Zometa Can Help Reduce Recurrence Risk of Hormone-Receptor-Positive Disease
Results from three studies all suggest that Zometa can help reduce the risk of cancer recurrence when it's started right after surgery to treat hormone-receptor-positive early-stage breast cancer in postmenopausal and older premenopausal women.
1–3 of 3 articles
